InMed Pharmaceuticals, Inc. (IMLFF) Adds to Its Drug Development Pipeline
A pre-clinical stage biopharmaceutical company, InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) has revealed two additions to its drug development pipeline. An expedited drug development timeline is now in place for INM-750 for epidermolysis bullosa (EB), with a potential market of about $1 billion. The disease is characterized by fragile skin in children. The company has also announced the development of INM-085 for glaucoma, which represents a potential global market of over $5 billion. Resulting in a defect in the connective tissue between the dermis and epidermis, most often caused by a lack of keratins, EB currently has no medication-based treatments. Multiple…